Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. (1st February 2022)

• Record Type: Journal Article
• Authors: Cromer, Deborah; Reynaldi, Arnold; Steain, Megan; Triccas, James A; Davenport, Miles P; Khoury, David S
• Is Part Of: Clinical infectious diseases. Volume 75:Number 1(2022)
• Page Start: e878
• Page End: e879
• Publication Date: 2022-02-01
• Subjects: Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac075
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other messenger RNA (mRNA) vaccines. Here we show that the low efficacy follows from the dose used and the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and is predicted by the neutralizing antibody response induced by the vaccine.